78 related articles for article (PubMed ID: 17971607)
1. Caution should be used when interpreting alterations affecting the exon 3 of the BRCA2 gene in breast/ovarian cancer families.
Díez O; Gutiérrez-Enríquez S; Ramón y Cajal T; Alonso C; Balmaña J; Llort G
J Clin Oncol; 2007 Nov; 25(31):5035-6; author reply 5036-8. PubMed ID: 17971607
[No Abstract] [Full Text] [Related]
2. Screening for large rearrangements of the BRCA2 gene in Spanish families with breast/ovarian cancer.
Gutiérrez-Enríquez S; de la Hoya M; Martínez-Bouzas C; Sanchez de Abajo A; Ramón y Cajal T; Llort G; Blanco I; Beristain E; Díaz-Rubio E; Alonso C; Tejada MI; Caldés T; Diez O
Breast Cancer Res Treat; 2007 May; 103(1):103-7. PubMed ID: 17063271
[TBL] [Abstract][Full Text] [Related]
3. MLPA screening in the BRCA1 gene from 1,506 German hereditary breast cancer cases: novel deletions, frequent involvement of exon 17, and occurrence in single early-onset cases.
Engert S; Wappenschmidt B; Betz B; Kast K; Kutsche M; Hellebrand H; Goecke TO; Kiechle M; Niederacher D; Schmutzler RK; Meindl A
Hum Mutat; 2008 Jul; 29(7):948-58. PubMed ID: 18431737
[TBL] [Abstract][Full Text] [Related]
4. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
[TBL] [Abstract][Full Text] [Related]
5. BRCA1 and BRCA2 point mutations and large rearrangements in breast and ovarian cancer families in Northern Poland.
Ratajska M; Brozek I; Senkus-Konefka E; Jassem J; Stepnowska M; Palomba G; Pisano M; Casula M; Palmieri G; Borg A; Limon J
Oncol Rep; 2008 Jan; 19(1):263-8. PubMed ID: 18097605
[TBL] [Abstract][Full Text] [Related]
6. Hereditary breast and ovarian cancer syndrome.
ACOG Committee on Practice Bulletins
Gynecol Oncol; 2009 Apr; 113(1):6-11. PubMed ID: 19309638
[No Abstract] [Full Text] [Related]
7. Large BRCA1 and BRCA2 genomic rearrangements in Danish high risk breast-ovarian cancer families.
Hansen Tv; Jønson L; Albrechtsen A; Andersen MK; Ejlertsen B; Nielsen FC
Breast Cancer Res Treat; 2009 May; 115(2):315-23. PubMed ID: 18546071
[TBL] [Abstract][Full Text] [Related]
8. Influence of race/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancer.
Forman AD; Hall MJ
Breast J; 2009; 15 Suppl 1():S56-62. PubMed ID: 19775331
[TBL] [Abstract][Full Text] [Related]
9. One risk fits all?
De Bock GH; Mourits MJ; Oosterwijk JC
J Clin Oncol; 2007 Aug; 25(22):3383-4; author reply 3384. PubMed ID: 17664491
[No Abstract] [Full Text] [Related]
10. BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer.
Thomassen M; Hansen TV; Borg A; Lianee HT; Wikman F; Pedersen IS; Bisgaard ML; Nielsen FC; Kruse TA; Gerdes AM
Acta Oncol; 2008; 47(4):772-7. PubMed ID: 18465347
[TBL] [Abstract][Full Text] [Related]
11. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
12. Identification of a novel BRCA1 large genomic rearrangement in a Spanish breast/ovarian cancer family.
Palanca Suela S; Esteban Cardeñosa E; Barragán González E; Oltra Soler S; de Juan Jiménez I; Chirivella González I; Segura Huerta A; Guillén Ponce C; Martínez de Dueñas E; Bolufer Gilabert P;
Breast Cancer Res Treat; 2008 Nov; 112(1):63-7. PubMed ID: 18060491
[TBL] [Abstract][Full Text] [Related]
13. Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families of Eastern Spain.
Esteban Cardeñosa E; Bolufer Gilabert P; Palanca Suela S; Oltra Soler S; Barragán González E; Velasco Sampedro E; Chirivella González I; Segura Huerta A; Guillén Ponce C; Martínez de Dueñas E;
Breast Cancer Res Treat; 2008 Nov; 112(1):69-73. PubMed ID: 18060494
[TBL] [Abstract][Full Text] [Related]
14. Receiving inconclusive genetic test results: an interpretive description of the BRCA1/2 experience.
Maheu C; Thorne S
Res Nurs Health; 2008 Dec; 31(6):553-62. PubMed ID: 18449940
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial of a breast/ovarian cancer genetic testing decision aid used as a communication aid during genetic counseling.
Wakefield CE; Meiser B; Homewood J; Taylor A; Gleeson M; Williams R; Tucker K;
Psychooncology; 2008 Aug; 17(8):844-54. PubMed ID: 18613319
[TBL] [Abstract][Full Text] [Related]
16. The variants BRCA1 IVS6-1G>A and BRCA2 IVS15+1G>A lead to aberrant splicing of the transcripts.
Gutiérrez-Enríquez S; Coderch V; Masas M; Balmaña J; Diez O
Breast Cancer Res Treat; 2009 Sep; 117(2):461-5. PubMed ID: 18712473
[TBL] [Abstract][Full Text] [Related]
17. The c.156_157insAlu BRCA2 rearrangement accounts for more than one-fourth of deleterious BRCA mutations in northern/central Portugal.
Peixoto A; Santos C; Rocha P; Pinheiro M; Príncipe S; Pereira D; Rodrigues H; Castro F; Abreu J; Gusmão L; Amorim A; Teixeira MR
Breast Cancer Res Treat; 2009 Mar; 114(1):31-8. PubMed ID: 18363094
[TBL] [Abstract][Full Text] [Related]
18. Towards more effective and equitable genetic testing for BRCA1 and BRCA2 mutation carriers.
James PA; Harris M; Lindeman GJ; Mitchell G
J Med Genet; 2008 Nov; 45(11):765-6. PubMed ID: 18978334
[No Abstract] [Full Text] [Related]
19. Cancer risk assessment and the genetic counseling process: using hereditary breast and ovarian cancer as an example.
Prucka SK; McIlvried DE; Korf BR
Med Princ Pract; 2008; 17(3):173-89. PubMed ID: 18408385
[TBL] [Abstract][Full Text] [Related]
20. BRCA screening.
Obstet Gynecol; 2008 May; 111(5):1205-6. PubMed ID: 18448758
[No Abstract] [Full Text] [Related]
[Next] [New Search]
